Docetaxel / Ferroptosis Cancer Research Results

docx, Docetaxel: Click to Expand ⟱

Features:

Docetaxel, (brand name Taxotere) is a chemotherapy medication used to treat breast cancer, head and neck cancer, stomach cancer, prostate cancer and non-small-cell lung cancer.
Docetaxel is a microtubule-stabilizing agent (taxane). It binds β-tubulin and promotes microtubule polymerization / prevents depolymerization, causing mitotic arrest (G2/M) and downstream cell death.
Clinically important constraints:
-Neutropenia / febrile neutropenia are major dose-limiting toxicities.
-Premedication with dexamethasone is standard to reduce fluid retention and hypersensitivity reactions.
-Metabolism is mainly CYP3A4, so strong CYP3A4 inhibitors/inducers (and grapefruit) can materially change exposure.

Rank	Pathway / Axis	Cancer / Tumor Context	Normal Tissue Context	TSF	Primary Effect	Notes / Interpretation
1	Microtubule stabilization (β-tubulin) → mitotic spindle dysfunction	Microtubule dynamics ↓; mitotic progression fails	Also impacts normal proliferating cells	P, R	Core cytotoxic mechanism	Taxane class MOA: stabilizes microtubules and blocks depolymerization, disrupting mitosis.
2	Mitotic arrest (G2/M checkpoint pressure)	G2/M arrest ↑; proliferation ↓	Bone marrow / GI epithelium vulnerability ↑	R, G	Cell-cycle blockade	Mitotic arrest is the key phenotype linking microtubule disruption to cell death outcomes.
3	Intrinsic apoptosis (mitochondrial) secondary to mitotic catastrophe	Apoptosis ↑ (context); caspase activation ↑	↔ / tissue injury possible at high exposure	G	Death execution	Cell death often occurs after prolonged mitotic arrest (mitotic catastrophe → apoptosis).
4	Neutropenia / marrow suppression (on-target toxicity)	—	Neutrophils ↓; febrile neutropenia risk ↑	R, G	Dose-limiting toxicity	Major clinical constraint; risk increases with dose and interacting drugs.
5	Hypersensitivity reactions	—	Hypersensitivity risk ↑ (especially early infusions)	P, R	Acute infusion risk	Premedication is used to reduce frequency/severity of hypersensitivity reactions.
6	Fluid retention / capillary leak tendency	—	Fluid retention ↑ (can be severe)	R, G	Key non-hematologic toxicity	Dexamethasone premedication is standard to reduce incidence and severity.
7	Combination leverage (sensitization with other agents)	Synergy reported in multiple regimens	Toxicity may ↑ depending on partner drug	G	Regimen-driven efficacy	Docetaxel is commonly used in multi-agent protocols; outcome is regimen- and tumor-type-specific.
8	Pharmacokinetics (CYP3A4 metabolism)	Exposure ↑ with strong CYP3A4 inhibitors; ↓ with inducers	Exposure shifts → toxicity/efficacy shifts	P, R	Interaction driver	Docetaxel is primarily cleared by CYP3A4; strong inhibitors can raise levels substantially.
9	Grapefruit / intestinal CYP3A4 inhibition (interaction risk)	Potential exposure ↑ (context)	Potential toxicity ↑ (context)	P, R	Diet–drug interaction	Grapefruit can inhibit intestinal CYP3A4; docetaxel is a CYP3A4 substrate, so avoidance is commonly advised.
10	Parameter dependence (dose/schedule; weekly vs q3wk)	Mechanism constant; tolerability differs by schedule	Toxicity profile differs by schedule	—	Translation constraint	Clinical outcomes and toxicity balance are schedule-dependent (protocol-specific).
11	ROS generation (secondary to mitotic stress)	ROS ↑ (mitochondrial); lipid peroxidation ↑ (reported)	Oxidative injury possible	R, G	Stress amplification	ROS increase is secondary to mitotic arrest and mitochondrial dysfunction, not a primary redox drug effect.
12	NRF2 antioxidant response	NRF2 ↑ (adaptive; reported in resistant models)	Protective antioxidant upshift	R, G	Resistance mechanism	NRF2 activation may reduce docetaxel sensitivity by increasing antioxidant capacity (GSH, NQO1, HO-1).

Time-Scale Flag (TSF): P / R / G

P: 0–30 min (binding and immediate microtubule dynamic suppression begins)
R: 30 min–3 hr (mitotic checkpoint engagement; acute infusion effects)
G: >3 hr (mitotic catastrophe, apoptosis, tissue-level toxicities)

Ferroptosis, Ferroptosis: Click to Expand ⟱

Source:

Type: type of cell death

Type of programmed cell death dependent on iron.
Ferroptosis is a form of regulated cell death characterized by the accumulation of lipid peroxides to lethal levels. It is distinct from other forms of cell death, such as apoptosis, necrosis, and autophagy. The process of ferroptosis is heavily dependent on iron metabolism and reactive oxygen species (ROS).
The accumulation of lipid peroxides is a hallmark of ferroptosis. This can occur when the antioxidant defenses, such as glutathione and selenoproteins, are overwhelmed or inhibited. Many cancer cells upregulate GPX4 to evade ferroptosis, making it a potential target for therapy. It has been described that GPX4, xCT and ACSL-4 are the main targets in the regulation of ferroptosis.

Scientific Papers found: Click to Expand⟱

2575-

ART/DHA,

docx,

Artemisia santolinifolia-Mediated Chemosensitization via Activation of Distinct Cell Death Modes and Suppression of STAT3/Survivin-Signaling Pathways in NSCLC

in-vitro,

Lung,

H23

AS at concentrations of 100 and 200 μg/mL in combination with DTX at concentrations of 0.5, 1 and 2.5 nM for 48 h.

ChemoSen↑, GPx4↓, ROS↑, Ferroptosis↑, eff↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Redox & Oxidative Stress ⓘ

Ferroptosis↑, 1, GPx4↓, 1, ROS↑, 1,

Cell Death ⓘ

Ferroptosis↑, 1,

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1, eff↑, 1,
Total Targets: 6

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: Ferroptosis, Ferroptosis

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells